IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...

In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK875.00. The company’s shares closed ...

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.

It hasn't been a great period for investors in Novo Nordisk (NYSE: NVO) despite its ongoing status as one of the pharmaceutical industry's apex competitors in the field of cardiometabolic drugs.

Medicare is preparing to negotiate prices on GLP-1 drugs such as Ozempic. Novo Nordisk investors could see the news put $14.3 billion in Medicare revenue at risk. Viking Therapeutics stock ...

Jan 17 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. Looking at options history for Novo Nordisk (NYSE:NVO) we detected 21 trades. If we consider the ...

The Centers for Medicare and Medicaid Services (CMS) released its second round of drug negotiation targets, a list of 15 drugs under Medicare Part D, including Novo Nordisk's (NVO) blockbuster GLP-1s.

Novo Nordisk's (NVO) GLP-1 weight loss drugs, Ozempic and Wegovy, will be targeted in the next round of Medicare price negotiations in 2027, along with 13 other medications. Seana Smith and Brad ...